{"id":"W2946386783","doi":"10.1016/s1470-2045(19)30167-6","title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1681,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Medicine; Paclitaxel; Atezolizumab; Chemotherapy; Oncology; Nab-paclitaxel; Open label; Internal medicine; Lung cancer; Cisplatin; Cancer; Randomized controlled trial; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}